Clinical value and limitations of serum CA19-9 as a biomarker of pancreatic cancer

Linchuang Gandanbing Zazhi

卷:29

CHEN Da¹ 

[1] (Department of Gastroenterology, China-Japan Friendship Hospital, Beijing 100029, China);

关键词: pancreatic neoplasms;    antigens;    tumor-associated;    carbohydrate;   

DOI  :  

来源: DOAJ

【 摘 要 】

Timely diagnosis and effective treatment of pancreatic cancer remains a distinct clinical challenge. Serum carbohydrate antigen (CA19-9) has emerged as a promising biomarker of pancreatic tumors and clinical studies have indicated its potential benefit in diagnosis, prognosis, and management of the disease. Compared with other biomarkers, serum CA19-9 shows better sensitivity and specificity for diagnosis of pancreatic cancer, but many limitations exist. Besides general instances of false-positive results, serum CA19-9 is associated with a high rate of false-negative results for patients with the Lewis-negative phenotype. Therefore, while serum CA19-9 may be a clinically valuable biomarker of pancreatic cancer, its results should be confirmed with imaging and histological findings.

【 授权许可】

Unknown